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Abstract
Background: Filaggrin is a major protein in the epidermis. Several mutations in the filaggrin gene (FLG) have been
associated with a number of conditions. Filaggrin is expressed in the tympanic membrane and could alter its mechanical
properties, but the relationship between genetic variation in FLG and hearing has not yet been tested.
Methodology/Principal Findings: We examined whether loss-of function mutations R501X and 2282del4 in the FLG gene
affected hearing in children. Twenty eight hearing variables representing five different aspects of hearing at age nine years
in 5,377 children from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort were tested for association
with these mutations. No evidence of association was found between R501X or 2282del4 (or overall FLG mutation carrier
status) and any of the hearing phenotypes analysed.
Conclusions/Significance: In conclusion, carrier status for common filaggrin mutations does not affect hearing in children.
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Introduction
Filaggrin (filament aggregation protein) is a major protein in the
cornified envelope of the epidermis and is involved in maintaining
the skin barrier [1,2]. The filaggrin gene (FLG) in humans encodes
a polyprotein precursor (profilaggrin) which, after post-transla-
tional processing, results in several individual filaggrin polypep-
tides [3]. Filaggrin has been linked to several clinical phenotypes,
with filaggrin mutations being directly associated with the cause,
susceptibility to, or modification of the clinical expression of
several diseases including dermatological disorders [2]. Common
mutations in FLG have been implicated in the causation of
ichthyosis vulgaris and appear to be a major risk factor for atopic
dermatitis, asthma associated with atopic dermatitis, eczema,
sensitization to grass, house dust mite and cat dander, and
sensitization to multiple allergens [2,4,5]. Two of the most studied
mutations (R501X and 2282del4) are common in populations of
European ancestry [6]. Both R501X and 2282del4 are loss-of
function mutations leading to truncation of filaggrin translation by
creating premature termination codons [7]. Both mutations have a
complex role both in Mendelian disease and in complex diseases.
An example is ichthyosis vulgaris. R501X and 2282del4 have been
suggested to be the cause of ichthyosis vulgaris in 15 families and
isolated cases, acting in a semidominant fashion with incomplete
penetrance [7]. Homozygotes for either mutation or compound
heterozygous are severely affected, with heterozygotes only mildy
affected [7]. Additional reports confirmed the role of R501X and
2282del4 on ichthyosis vulgaris ([8] for review). One of these
studies [9] showed that heterozygous individuals were also severely
affected, suggesting that additional mutations might be present in
these patients.
It has been shown that loss or reduction of filaggrin leads to
impaired keratinization and defective skin barrier [7]. In fact,
although it has not been pursued in the context of filaggrin
mutations, filaggrin is also expressed in the tympanic membrane,
where it is involved in the soft keratinization of the epidermal layer
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R501X N Mean SD F P
Right ear
Air conduction hearing threshold (dB HL) 0.5 kHz AA 4952 6.20 7.24 0.12 0.7328
Aa 219 6.37 6.75
1 kHz AA 5026 4.38 7.66 0.23 0.6291
Aa 223 4.13 6.61
2 kHz AA 5025 4.04 7.33 0.47 0.4914
Aa 223 3.70 5.80
4 kHz AA 5024 3.85 8.34 1.12 0.2908
Aa 223 3.25 7.90
8 kHz AA 4932 9.05 10.09 0.34 0.5583
Aa 218 8.65 9.10
Average 0.5, 1, 2, 4, 8 kHz AA 4926 5.47 6.34 0.33 0.5656
Aa 217 5.22 5.63
Left ear
Air conduction hearing threshold (dB HL) 0.5 kHz AA 4954 6.48 7.30 0.02 0.8952
Aa 219 6.42 6.57
1 kHz AA 5025 4.52 7.67 2.49 0.1150
Aa 223 3.70 5.94
2 kHz AA 5023 4.24 7.53 0.76 0.3831
Aa 223 3.79 6.07
4 kHz AA 5022 4.68 8.60 0.63 0.4289
Aa 222 4.21 7.10
8 kHz AA 4931 9.16 10.36 0.69 0.4078
Aa 217 8.57 9.64
Average 0.5, 1, 2, 4, 8 kHz AA 4929 5.78 6.30 1.18 0.2781
Aa 216 5.31 5.19
Bone conduction hearing threshold (dB HL) 0.5 kHz AA 4859 21.24 6.53 0.06 0.8069
Aa 215 21.35 6.02
1 kHz AA 5000 22.30 6.52 0.07 0.7956
Aa 222 22.18 5.81
2 kHz AA 4868 0.95 7.26 0.20 0.6557
Aa 215 0.72 6.84
Average 0.5, 1, 2 kHz AA 4854 20.89 5.38 0.01 0.9085
Aa 215 20.93 5.01
Left ear
TEOAE amplitude (dB SPL) 1 kHz AA 3865 28.75 6.96 0.03 0.8677
Aa 164 28.66 7.56
2 kHz AA 3899 210.16 6.74 0.06 0.8092
Aa 165 210.29 6.55
3 kHz AA 3893 212.12 7.14 1.24 0.2661
Aa 166 212.75 7.05
4 kHz AA 3906 213.81 7.57 0.53 0.4680
Aa 166 214.24 6.86
Total response AA 3917 9.62 5.69 0.05 0.8229
Aa 166 9.52 5.36
Right ear
TEOAE amplitude (dB SPL) 1 kHz AA 3704 27.66 6.91 2.63 0.1048
Aa 154 26.73 7.20
2 kHz AA 3765 29.04 6.52 3.50 0.0615
Aa 154 28.04 6.11
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filaggrin has been localised immunohistochemically in middle ear
cholesteatoma in humans [11], this condition leading to an
alteration of epidermal differentiation in middle ear [12].
Expression of FLG in these locations affecting the cornified
envelope of the tympanic epidermis has the potential to influence
hearing. The high prevalence of FLG mutations could reflect
chance, but selective advantage through a trait such as hearing is
another possibility. We hypothesized that such changes would
affect air but not bone conduction as they affect tympanic
membrane and not neural mechanisms.
Clinical evidence available relates impaired keratinization to the
filaggrin mutations R501X and 2282del4. To date, there has been
no consideration of the possible effects with respect to filaggrin
expression in the tympanic membrane. Based on this evidence we
tested whether carrier status for a single copy of these mutations is
a risk or protective factor for hearing loss/enhanced hearing in an
epidemiological survey of 5,377 UK children with detailed
phenotypic information for a range of hearing phenotypes.
Materials and Methods
Participants
ALSPAC is a longitudinal, population-based birth cohort study
that recruited 14,541 pregnant women residing in Avon, United
Kingdom, with expected dates of delivery between April 1, 1991,
and December 31, 1992. There were 14,062 liveborn children.
The study protocol has been described previously [13,14] and
further details are available on the ALSPAC Web site (http://
www.bris.ac.uk/alspac). Ethical approval for all aspects of data
collection was obtained from the ALSPAC Law and Ethics
Committee (institutional review board 00003312). Written in-
formed consent for the study was obtained.
Genotyping
Genotyping was done as previously described [4]. In brief,
R501X and 2282del4 were genotyped with the TaqMan allelic
discrimination assays (Applied Biosystems, Foster City, California)
in 384-well plates. Double-checking with other technical ap-
proaches was performed in a substantial fraction of the samples,
including all the identified homozygotes of both variants and all
2282del4 carriers.
Hearing variables
All study participants were invited to a research clinic at 9 years
of age where five different hearing phenotypes were measured:
hearing thresholds, transient evoked (TE) otoacoustic emission
(OAE) amplitude, middle ear compliance and pressure.
For these phenotypes, a total of 28 variables were analysed:
hearing thresholds at five frequencies (0.5, 1, 2, 4 and 8 kHz) for
air conduction and three frequencies (0.5, 1, 2 kHz) for bone
conduction were measured.
Tympanometry was used to measure middle ear compliance
and middle ear pressure. TEOAE were evoked using a click
stimulus of approximately 70 dB SPL (linear mode), and the
response amplitude obtained for the total response and at
frequency bands 1–4 kHz. All measures (except bone conduction
thresholds) were obtained for both left and right ears.
Since both mutations are inactivating mutations likely to have
similar or identical effects and homozygotes and compound
heterozygotes are rare, we also undertook a combined analysis
(one degree of freedom) for each variable for FLG mutation carrier
vs FLG mutation non-carrier.
In addition to the analysis of each variable in all individuals, we
tested whether each of the two mutations was associated with
better versus worse hearing, using a cut off of ,=0 dB, both for
hearing thresholds (right and left), and for bone conduction acute
hearing thresholds. The effect of both mutations was also analysed
by testing the association between each of the mutations and better
versus worse cochlear function/middle ear transmission (worse
cochlear function defined as the bottom quartile of the TEOAE
amplitude distribution).
We tested whether R501X or 2282del4 associated with bilateral
middle ear effusion. Finally, we tested whether the filaggrin
R501X N Mean SD F P
3 kHz AA 3761 211.44 7.18 0.08 0.7736
Aa 154 211.27 6.76
4 kHz AA 3757 213.54 7.42 0.60 0.4401
Aa 152 214.01 7.07
Total response AA 3776 10.46 5.65 2.89 0.0894
Aa 154 11.25 5.46
Left ear
Tympanometry Middle ear compliance (cm
3) AA 4785 0.64 0.42 1.72 0.1895
Aa 208 0.68 0.47
Middle ear pressure (daPa) AA 4796 239.66 61.80 0.01 0.9430
Aa 207 239.35 68.24
Right ear
Tympanometry Middle ear compliance (cm
3) AA 4791 0.62 0.42 0.13 0.7215
Aa 206 0.63 0.43
Middle ear pressure (daPa) AA 4804 239.47 61.42 0.14 0.7119
Aa 204 237.84 64.31
doi:10.1371/journal.pone.0005784.t001
Table 1. cont.
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2282del4 N Mean SD F P
Right ear
Air conduction hearing threshold (dB HL) 0.5 kHz AA 4932 6.19 7.19 0.32 0.7243
Aa 238 6.55 7.83
aa 2 7.50 3.54
1 kHz AA 5010 4.32 7.53 2.29 0.1018
Aa 238 5.36 9.15
aa 2 7.50 3.54
2 kHz AA 5009 4.00 7.20 5.16 0.0057
Aa 238 4.39 8.43
aa 2 20.00 21.21
4 kHz AA 5008 3.80 8.30 0.51 0.5999
Aa 238 4.35 8.71
aa 2 2.50 3.54
8 kHz AA 4915 9.01 10.05 0.32 0.7282
Aa 234 9.53 10.09
aa 2 7.50 3.54
Average 0.5, 1, 2, 4, 8 kHz AA 4908 5.43 6.26 1.40 0.2456
Aa 234 6.06 7.29
aa 2 9.00 4.24
Left ear
Air conduction hearing threshold (dB HL) 0.5 kHz AA 4934 6.48 7.27 0.05 0.9520
Aa 238 6.37 7.20
aa 2 7.50 3.54
1 kHz AA 5009 4.48 7.59 0.03 0.9664
Aa 238 4.60 8.01
aa 2 5.00 7.07
2 kHz AA 5007 4.20 7.44 0.38 0.6855
Aa 238 4.62 8.19
aa 2 5.00 0.00
4 kHz AA 5005 4.67 8.54 0.34 0.7106
Aa 238 4.50 8.59
aa 2 0.00 7.07
8 kHz AA 4913 9.15 10.32 0.10 0.9009
Aa 234 8.85 10.60
aa 2 10.00 0.00
Average 0.5, 1, 2, 4, 8 kHz AA 4910 5.75 6.23 0.01 0.9889
Aa 234 5.81 6.99
aa 2 5.50 3.54
Bone conduction hearing threshold (dB HL) 0.5 kHz AA 4840 21.25 6.45 0.44 0.6461
Aa 233 21.05 7.72
aa 2 2.50 10.61
1 kHz AA 4984 22.30 6.39 0.58 0.5610
Aa 237 22.19 8.27
aa 2 2.50 3.54
2 kHz AA 4849 0.93 7.17 0.34 0.7145
Aa 233 1.03 8.62
aa 2 5.00 7.07
Average 0.5, 1, 2 kHz AA 4835 20.90 5.27 0.72 0.4870
Aa 233 20.74 7.19
aa 2 3.33 2.36
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Left ear
TEOAE amplitude (dB SPL) 1 kHz AA 3838 28.75 7.01 0.04 0.9621
Aa 191 28.68 6.62
aa 1 27.10 .
2 kHz AA 3871 210.15 6.73 0.17 0.8443
Aa 193 210.44 6.80
aa 1 210.60 .
3 kHz AA 3867 212.14 7.16 0.06 0.9387
Aa 192 212.32 6.63
aa 1 212.70 .
4 kHz AA 3880 213.82 7.56 0.15 0.8629
Aa 192 213.94 7.11
aa 1 217.60 .
Total response AA 3890 9.63 5.68 0.10 0.9026
Aa 193 9.45 5.50
aa 1 8.60 .
Right ear
TEOAE amplitude (dB SPL) 1 kHz AA 3668 27.62 6.93 0.04 0.9637
Aa 190 27.59 6.86
aa 1 25.80 .
2 kHz AA 3727 29.00 6.52 0.00 0.9970
Aa 192 29.00 6.18
aa 1 29.50 .
3 kHz AA 3722 211.38 7.17 2.23 0.1074
Aa 193 212.42 6.90
aa 1 26.00 .
4 kHz AA 3716 213.54 7.41 0.36 0.6982
Aa 193 213.85 7.28
aa 1 28.80 .
Total response AA 3738 10.50 5.66 0.17 0.8470
Aa 192 10.29 5.39
aa 1 11.90 .
Left ear
Tympanometry Middle ear compliance (cm
3) AA 4767 0.64 0.42 0.22 0.7987
Aa 225 0.65 0.40
aa 2 0.55 0.07
Middle ear pressure (daPa) AA 4776 239.73 62.29 0.32 0.7292
Aa 226 237.96 57.50
aa 2 210.00 14.14
Right ear
Tympanometry Middle ear compliance (cm
3) AA 4768 0.62 0.42 1.60 0.2028
Aa 228 0.67 0.44
aa 2 0.45 0.07
Middle ear pressure (daPa) AA 4780 239.37 61.61 0.14 0.8712
Aa 227 240.00 60.16
aa 2 217.50 10.61
doi:10.1371/journal.pone.0005784.t002
Table 2. cont.
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Status N Mean SD F P
Right ear
Air conduction hearing threshold (dB HL) 0.5 kHz 0 4716 6.18 7.21 0.62 0.4308
1 455 6.46 7.32
1 kHz 0 4790 4.33 7.57 1.42 0.2333
1 459 4.77 8.05
2 kHz 0 4789 4.02 7.26 0.14 0.7041
1 459 4.15 7.41
4 kHz 0 4788 3.83 8.31 0.00 0.9926
1 459 3.82 8.35
8 kHz 0 4700 9.03 10.09 0.02 0.8892
1 450 9.10 9.63
Average 0.5, 1, 2, 4, 8 kHz 0 4694 5.44 6.28 0.56 0.4543
1 449 5.67 6.56
Left ear
Air conduction hearing threshold (dB HL) 0.5 kHz 0 4718 6.48 7.31 0.04 0.8508
1 455 6.42 6.90
1 kHz 0 4789 4.51 7.66 0.58 0.4454
1 459 4.23 7.08
2 kHz 0 4787 4.21 7.50 0.02 0.8981
1 459 4.26 7.25
4 kHz 0 4786 4.69 8.60 0.71 0.3990
1 458 4.33 7.91
8 kHz 0 4699 9.18 10.35 0.86 0.3545
1 449 8.71 10.13
Average 0.5, 1, 2, 4, 8 kHz 0 4697 5.77 6.27 0.36 0.5510
1 448 5.59 6.20
Bone conduction hearing threshold (dB HL) 0.5 kHz 0 4628 21.25 6.47 0.05 0.8241
14 4 6 21.18 6.93
1 kHz 0 4765 22.31 6.42 0.31 0.5772
14 5 7 22.13 7.19
2 kHz 0 4637 0.94 7.18 0.01 0.9038
1 446 0.90 7.82
Average 0.5, 1, 2 kHz 0 4623 20.90 5.28 0.14 0.7128
14 4 6 20.80 6.22
Left ear
TEOAE amplitude (dB SPL) 1 kHz 0 3677 28.75 6.98 0.02 0.8939
13 5 2 28.70 7.08
2 kHz 0 3709 210.14 6.73 0.45 0.5047
13 5 5 210.39 6.71
3 kHz 0 3704 212.11 7.17 1.30 0.2538
13 5 5 212.56 6.83
4 kHz 0 3717 213.80 7.59 0.58 0.4452
13 5 5 214.12 7.01
Total response 0 3727 9.64 5.70 0.31 0.5792
1 356 9.46 5.45
Right ear
TEOAE amplitude (dB SPL) 1 kHz 0 3515 27.66 6.91 1.46 0.2271
13 4 3 27.19 7.02
2 kHz 0 3574 29.04 6.54 1.54 0.2153
Filaggrin Mutation and Hearing
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5784mutations associated with better hearing thresholds/TEOAE in
cases with type A tympanograms (i.e. no middle ear effusion).
Statistical analyses
The associations between each of the two mutations and
continuous variables were tested by means of one-way ANOVA
analyses. Analyses involving the discrete variable bilateral middle
ear effusion were performed by means of a Pearson x
2 contingency
test. All analyses were performed in SPSS ver. 15.0.
Results
Complete data on genotypic data and at least one hearing
variable were available for 5,377 children.
There were no significant deviations from Hardy-Weinberg
equilibrium for the mutations analysed (data not shown). The
allele frequencies observed for R501X (0.021) and 2282del4
(0.023) are consistent with the allele frequencies observed in other
studies (ranging from 0,021 to 0.041 for R501X, and from 0.005
to 0.019 for 2282del4) [9].
Tables 1 and 2 show the results from the association tests
between each of the 28 variables analysed and R501X and
2282del4 respectively. There was no single nominal association
between any of the 28 variables and R501X. For 2282del4, we
found a nominal association (P=0.0057) with air conduction
hearing threshold level at 2 kHz on the right ear, but no
association with the same hearing threshold for the left ear
(P=0.6855). The audiograms for two children homozygous for
2282del4 (who averaged right ear 2 kHz data which was
significant; P=0.0057) indicated an isolated right ear high
threshold (35 dB) for one subject, whereas the other subject and
both left ear values were near the population average. No
association was found between the 28 variables and overall FLG
mutation carrier vs non-carrier status (Table 3). The results
observed when considering the combined homozygote status
association (compound heterozygous for both mutations plus
homozygotes for 2282del4) were not remarkable (data not shown).
There was no association with better versus worse hearing in
either of the two mutations (data not shown). The analyses
involving enhanced or diminished bone conduction did not show
evidence of association with R501X (data not shown). A nominal
association (P=0.013) was found between the average bone
conduction better versus worse hearing and 2282del4 but there
was neither association nor evidence of any magnitude of
difference by genotype for R501X. The analyses involving better
versus worse cochlear function/middle ear transmission did not
show evidence of association with R501X or 2282del4 (data not
shown).
Table 4 shows the contingency tables for the phenotype bilateral
middle ear effusion for both R501X and 2282del4. There was no
relationship between FLG mutations and middle ear effusion. The
analysis of association between cases with type A tympanograms
(i.e. no middle ear effusion) and the hearing variables showed no
evidence of association with either mutation.
Discussion
This work is the first analysis of two common filaggrin
mutations (R501X and 2282del4) for possible effect on hearing
phenotypes. It was undertaken in a large (N=5,377) cohort of UK
children. These children were analysed in detail for a large
number of hearing variables when they were nine years old. We
did not find any support for the hypothesis that FLG mutation
carrier status, via known expression in the tympanic membrane,
might affect hearing. Two instances of nominal association were
found in our study. However, both instances may be the result of
type-I error, since we conducted 140 tests. The correction for
multiple testing results in a limit of P=0.0004 to reject the null
Status N Mean SD F P
13 4 5 28.58 6.16
3 kHz 0 3569 211.39 7.19 1.60 0.2060
13 4 6 211.90 6.87
4 kHz 0 3565 213.52 7.42 0.77 0.3797
13 4 4 213.89 7.19
Total response 0 3585 10.47 5.67 0.64 0.4242
1 345 10.72 5.44
Left ear
Tympanometry Middle ear compliance (cm
3) 0 4562 0.64 0.42 1.64 0.2007
1 431 0.66 0.44
Middle ear pressure (daPa) 0 4572 239.71 62.01 0.06 0.8113
14 3 1 238.97 62.74
Right ear
Tympanometry Middle ear compliance (cm
3) 0 4565 0.62 0.42 2.19 0.1389
1 432 0.65 0.44
Middle ear pressure (daPa) 0 4579 239.44 61.49 0.02 0.8934
14 2 9 239.02 62.08
doi:10.1371/journal.pone.0005784.t003
Table 3. cont.
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observed in our study. Furthermore, these nominal associations
were not consistent between the two different FLG mutations.
Our study was well powered (N=5,377). This reduces the
chance of false negatives. Therefore, our conclusions of no effect of
R501X and 2282del4 on hearing thresholds or on otoacoustic
emissions are robust. The same applies to our results indicating no
effect of FLG mutations on tympanic membrane compliance,
middle ear pressure or incidence of middle ear effusion. However,
our results derive from a UK sample of nine year old children. It
remains possible that there might be genotype-dependent effects in
other age ranges and populations.
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R501X 2282del4
AA Aa AA Aa aa
Bilateral A Observed 3881 162 3856 186 2
Expected 3874.00 169.00 3861.22 181.25 1.53
Bilateral B Observed 62 2 63 1 0
Expected 61.32 2.68 61.11 2.87 0.02
Bilateral C1 Observed 121 3 118 6 0
Expected 118.82 5.18 118.40 5.56 0.05
Bilateral C2 Observed 58 5 61 2 0
Expected 60.37 2.63 60.15 2.82 0.02
Unilateral B Observed 164 8 168 4 0
Expected 164.81 7.19 164.23 7.71 0.07
Other Observed 780 41 783 38 0
Expected 786.68 34.32 783.89 36.80 0.31
Pearson x
2 P=0.402 P=0.937
Type A indicates normal middle ear function. Type B indicates middle ear effusion. Type C1 indicates slight negative middle ear pressure. Type C2 indicates negative
middle ear pressure. Other indicates grommet, perforation, or type C2 tympanogram in at least one ear. Expected correspond to the expected contingency values were
the null hypothesis is that the probabilities for each phenotype are independent of the mutation.
doi:10.1371/journal.pone.0005784.t004
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